Affordable Access

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

Authors
Journal
British Journal of Cancer
0007-0920
Publisher
Nature Publishing Group
Publication Date
Keywords
  • Research Article
Disciplines
  • Biology

Abstract

The androstenedione derivative, exemestane (FCE 24304), is a new orally active irreversible aromatase inhibitor. Fifty-six post-menopausal advanced breast cancer patients entered this study to evaluate the activity of four low exemestane doses in reducing oestrogen levels. The drug's tolerability and clinical efficacy were also assessed. Exemestane was orally administered to four consecutive groups at daily doses of 25, 12.5, 5 and 2.5 mg, and the changes in oestrogen, gonadotrophins, sex-hormone binding globulin and dehydroepiandrosterone sulphate levels were evaluated. Drug selectivity was studied by measuring 17-hydroxycorticosteroid urinary levels. After 7 days of treatment, mean oestrone and oestradiol levels had decreased by respectively 64% and 65% (a decrease which was maintained over time); in the 2.5 mg group, oestrone sulphate levels also decreased by 74%. Gonadotrophin levels were significantly higher, whereas no changes in the other serum hormone levels or any interference with adrenal synthesis were detected. Treatment tolerability was satisfactory: nausea and dyspepsia were reported in 16% of patients. The overall objective response rate was 18%. In conclusion, exemestane is effective in reducing oestrogen levels at all of the tested doses and shows interesting clinical activity.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Endocrinological and clinical evaluation of exemes...

on British Journal of Cancer October 1995

Exemestane, a new steroidal aromatase inhibitor of...

on Biochimica et Biophysica Acta... Jan 01, 2002

Exemestane, a new steroidal aromatase inhibitor of...

on Biochimica et Biophysica Acta Jul 18, 2002

Exemestane (FCE 24304), a new steroidal aromatase...

on The Journal of Steroid Biochem... September 1992
More articles like this..